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Editorial on the Research Topic
Genetics of Kidney Diseases
Worldwide, more than 850 million people have chronic kidney disease (CKD) (Jager et al., 2019).
CKD can be caused by a variety of individual diseases including primary kidney diseases and
systemic diseases such as diabetes. Diabetic kidney disease (DKD) worldwide develops in ∼40%
of patients with diabetes and is the leading cause of CKD (Alicic et al., 2017). CKD is accompanied
by an excessively elevated risk of premature mortality, particularly due to its predisposition to
accelerated cardiovascular disease. In more than 10% of CKD patients the primary cause of disease
is unknown (Groopman et al., 2018). It is crucial to increase the yield of the diagnostic work-up in
these patients, since specific treatments exist for several kidney diseases.
Recent developments in genetics including next-generation sequencing (NGS) have strongly
enhanced the diagnostic potential for patients with CKD. Moreover, novel genetic tools have
contributed to growing insight in the etiology of both monogenic and multifactorial types of
CKD. This is strongly illustrated by the rare disease atypical hemolytic uremic syndrome (aHUS),
for which now numerous causal mutations in complement-related genes have been identified
(Jokiranta, 2017). In this Research Topic, Schönauer et al. have demonstrated the case of a patient
with aHUS, which was caused by a novel splice site variant in the complement factor H gene.
Another paper in this Research Topic (Li P. et al.) also reports on a splice site mutation, in
this case in the alpha-galactosidase A (GLA) gene. Several mutations in this gene have been
previously found that lead to Fabry disease, a rare X-linked recessive hereditary systemic disorder
of glycosphingolipid metabolism caused by totally or partially decreased activity ofGLA (Simonetta
et al., 2018). The aforementioned studies illustrate the power of genetic tools to reach a clinically
relevant diagnosis driving the CKD phenotype (although the disorder may also affect other organ
system as for example in Fabry disease), which may have therapeutic consequences as specific
treatments exist both for aHUS and Fabry.
At the same time, clinical practice in nephrology is facing new challenges including optimal
patient selection, implementation, counseling, and therapeutic consequences of the outcomes of
NGS-based diagnostics. De Haan et al. discuss the advantages and limitations of NGS-based tools,
and specifically focus on how these tools could improve diagnostic yield in patients with CKD
of unknown or unclear etiology. In fact, further prospective cohort studies are needed to define
the optimal positioning of NGS-based genetic testing in the diagnostic workup of CKD with
unknown etiology.
For multifactorial diseases, which affect the majority of CKD patients, the impact of the
“genomic revolution” has so far been relatively limited. At the same time these advances, among
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others in terms of technology and infrastructure, have the
potential to revolutionize precision medicine in the field
of nephrology. This is illustrated by International Genetics
& Translational Research in Transplantation Network
(iGeneTRAiN): a multi-site consortium that encompasses
>45 genetic studies with genome-wide genotyping from over
51,000 transplant samples, including genome-wide data from
>30 kidney transplant cohorts (n = 28,015) (Fishman et al.).
The potential of large-scale collaborations such as iGeneTrain
to contribute to the understanding of disease etiologies has
already been shown in several studies in CKD and kidney
transplantation (Snoek et al., 2018; Reindl-Schwaighofer et al.,
2019). Furthermore, genome-wide association studies (GWAS)
performed in diverse populations can be useful to define the
robustness of previously identified CKD risk loci such as the
APOL1 across different ethnicities. This multi-ethnic study by
Lin et al. also identified a novel risk locus for CKD near the
NMT2 gene. Yet another approach is to study very specific
high-risk populations. Thomson et al. performed a GWAS of
limited size in a cohort of Australian Aboriginal Tiwi islanders, a
population prone to develop CKD that had not been extensively
studied before. The authors identified a variant near the CRIM1
gene that was associated with albuminuria, and remained
significant after adjusting for multiple testing (Thomson et al.).
Another important application of genetic tools is in patient
stratification, and in the identification of modifier genes that
enhance susceptibility to morbidities such as CKD and DKD.
This particularly applies to patients with type 1 and type 2
diabetes, the most common cause of end-stage kidney disease
(ESRD) worldwide (Gu). Valoti et al. identified a variant in
the complement factor H (CFH) gene that confer patients
with type 2 diabetes at increased risk of microalbuminuria
and cardiovascular complications. Moreover, patients carrying
the variant were less likely to benefit from ACEi therapy.
Although CFHmutations are well-known to predispose to aHUS
(Jokiranta, 2017), it was so far not known that CFH variants could
enhance susceptibility to adverse kidney outcomes in patients
with diabetes. Two variants in the beta-actin (ACTB) gene were
identified in another study, which were associated with a higher
risk of DKD in a large cohort of patients with type 2 diabetes (Li
M. et al.). Thereby, ACTB, as a housekeeping gene, is suggested
preferably not to be used as internal control for gene expression
studies at the mRNA and protein levels in diabetes and DKD.
Despite efforts summarized above to find missing pieces of
the genetic puzzle in CKD and DKD, it remains challenging
to explain the complete heritability with currently available
methods and datasets. Although studies beyond “conventional
GWAS” have focused on telomeres, copy number variants,
mitochondrial DNA and sex chromosomes, there remains
considerable unexplained heritability in CKD and DKD
(Cañadas-Garre et al.).
Furthermore, in addition to the multitude of information
coming to us from genetic studies, we are facing new challenges
as these data need to be interpreted in the context of other data
dimensions including proteomics, single-cell RNA-sequencing,
metabolomics, and the microbiome (Parsa et al., 2013; Hanna
et al., 2017). Therefore, in order to profoundly impact clinical
practice, comprehensive approaches are needed, particularly
through the integration of multiple-omics data.
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